TOMI Environmental Solutions, Inc. develops and sells disinfection and decontamination technology aimed at controlling bacteria, viruses, and other pathogens in indoor air and on surfaces. I follow TOMZ because its core technology addresses hygiene and biosecurity needs across healthcare, pharmaceutical, food production, and commercial settings. The company is best known for its SteraMist brand, built around a proprietary hydrogen peroxide-based application method. To get a quick sense of its positioning, I also checked this using Tickeron’s AI Screener to compare it with peers in the broader industry.
TOMI Environmental Solutions traces its roots to 1979 and is headquartered in Frederick, Maryland, where it operates with a relatively small team of roughly 20 employees. The company is led by Chief Executive Officer Halden Stuart Shane. As a micro-cap issuer listed on the Nasdaq, TOMZ represents a small company by market value, which is an important consideration for investors evaluating its risk profile.
The company's business model centers on a single core technology platform. SteraMist uses Binary Ionization Technology (BIT), a patented process that converts a low-percentage hydrogen peroxide solution into a fine mist or fog. This application method is designed to disinfect and decontaminate air and surfaces efficiently while using a lower concentration of hydrogen peroxide than some traditional approaches. TOMI markets a range of hardware products built around this technology, including portable and stationary systems for different environments.
TOMI organizes its commercial activities into four primary business segments: Hospital-HealthCare, Life Sciences, Commercial, and Food Safety. These segments reflect the company's efforts to serve diverse end markets, from hospital rooms and pharmaceutical cleanrooms to food processing facilities and general commercial spaces. Revenue is generated through the sale of SteraMist equipment, related consumables, and associated service offerings.
Within the broader disinfection and infection-control industry, TOMZ competes with larger, better-capitalized providers of cleaning, sanitization, and decontamination solutions. The company differentiates itself through its proprietary Binary Ionization Technology and its focus on hydrogen peroxide-based applications that aim to reduce chemical residue and environmental impact compared with certain alternatives. However, its small size and limited workforce mean it must compete on technology differentiation and niche applications rather than scale.
The company serves both domestic and international customers and has described efforts to expand its regulatory approvals in markets such as Europe. Its positioning in regulated environments—including healthcare and life sciences—means that certifications and compliance approvals can serve as meaningful competitive milestones for the business.
Investor interest in TOMZ is driven by several long-term themes. First, heightened awareness of biosecurity, infection prevention, and environmental decontamination has supported demand for technologies like SteraMist across healthcare and food safety settings. Second, the company's proprietary technology provides a potential competitive moat in a specialized niche, and it has pursued certifications and regulatory approvals that could open access to additional markets such as pharmaceutical cleanrooms.
Third, the company's focus on a lower-concentration, environmentally friendlier hydrogen peroxide solution aligns with broader sustainability trends in industrial hygiene. These factors give TOMZ a distinct—if small—market position that attracts attention from investors interested in specialized technology plays. It is important to note, however, that the company's financial profile remains that of an early-stage growth business, and investors often weigh its technology narrative against its modest scale and historical profitability.
Investing in TOMZ carries several notable risks. As a micro-cap company with a small number of employees, the business has limited operational scale and may be more sensitive to the loss of key customers or personnel. Customer concentration, dependence on a single core technology, and competition from larger, well-funded rivals are ongoing considerations. The company's financial profile has historically reflected a growth-stage business, and its ability to achieve consistent profitability is not guaranteed.
Macroeconomic sensitivity is another factor: capital-equipment purchasing in healthcare, life sciences, and food production can fluctuate with broader economic conditions and customer budgets. Regulatory factors also matter, since sales into healthcare and cleanroom markets depend on obtaining and maintaining certifications. Finally, corporate actions such as capital-raising or restructuring—common among small issuers—can affect shareholder value and warrant careful review of the company's filings.
In my research process, I often turn to Tickeron’s AI Screener to evaluate specialized names like TOMZ against broader industry benchmarks. This AI-powered platform helps identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. It allows users to efficiently screen thousands of stocks and ETFs to match their own investment strategies, which can be especially useful when assessing micro-cap opportunities in niche sectors.
TOMI Environmental Solutions occupies a specialized position in the disinfection and decontamination market, anchored by its proprietary SteraMist technology and Binary Ionization Technology platform. Its focus on healthcare, life sciences, commercial, and food safety applications gives the company a diversified set of end markets, even as its small size defines a distinct risk profile. For investors, TOMZ represents a niche, technology-driven micro-cap with a recognizable brand and exposure to long-running themes in biosecurity and environmental hygiene.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Stochastic Oscillator for TOMZ moved out of overbought territory on November 18, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 53 similar instances where the indicator exited the overbought zone. In 49 of the 53 cases the stock moved lower. This puts the odds of a downward move at 90%.
The 10-day RSI Indicator for TOMZ moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 26 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TOMZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
TOMZ broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on TOMZ as a result. In 68 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for TOMZ just turned positive on October 27, 2026. Looking at past instances where TOMZ's MACD turned positive, the stock continued to rise in 34 of 44 cases over the following month. The odds of a continued upward trend are 77%.
TOMZ moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TOMZ crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +22.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where TOMZ advanced for three days, in 175 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 85 of 119 cases where TOMZ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
The Tickeron Seasonality Score of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TOMZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.229) is normal, around the industry mean (10.189). P/E Ratio (-4.125) is within average values for comparable stocks, (-16.372). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (0.975). Dividend Yield (0.000) settles around the average of (0.050) among similar stocks. P/S Ratio (1.637) is also within normal values, averaging (251.106).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TOMZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry IndustrialSpecialties